SAB Biotherapeutics News

SAB Biotherapeutics Enhances Board With Medical Expert

TipRanksMay 8 18:14

Press Release: SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmac

Dow JonesMay 6 19:15

SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

SAB Biotherapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow JonesApr 17 01:38

HC Wainwright & Co. : The SAB Biotherapeutics (SABS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.

HC Wainwright & Co. : The SAB Biotherapeutics (SABS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.

Zhitong FinanceApr 17 01:31

Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)

TipRanksApr 16 22:00

Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics with a Buy and maintains $25 price target.

Analyst UpgradesApr 16 19:41

SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far

SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far

BenzingaApr 16 19:17

SAB Biotherapeutics Provides SAB-142 Trial Update

MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is

GlobeNewswireApr 16 19:15

SAB Biotherapeutics Advances SAB-142 in Phase One Trials

TipRanksApr 16 05:33

SAB Biotherapeutics to Present at INNODIA Annual Meeting

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is

GlobeNewswireApr 8 19:15

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human

GlobeNewswireApr 4 19:15

SAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy Rating

TipRanksApr 4 14:35

SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 2 20:50

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6

HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics with a Buy and lowers the price target from $10 to $6.

Analyst UpgradesApr 2 20:40

SAB Biotherapeutics GAAP EPS of -$7.64 Misses by $3.43, Revenue of $2.24M Beats by $1.12M

Seeking AlphaMar 29 19:17

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed

GlobeNewswireMar 29 19:15

SAB Biotherapeutics, Navy Medical Research Command Initiate Safety Study for Influenza Treatment; Shares Decline

SAB Biotherapeutics (SABS) said Monday that the Navy Medical Research Command will conduct a safety study of SAB-176, a potential treatment for influenza type A and B, as part of a research and develo

MT NewswiresMar 26 01:17

SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center to Advance Potential Influenza Treatment

SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is

GlobeNewswireMar 25 22:15

SAB Biotherapeutics Secures Leadership With New Executive Contracts

TipRanksMar 9 05:42

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing

GlobeNewswireFeb 23 21:00